神経芽細胞腫(Neuroblastoma):治療薬開発パイプライン動向(2016年下半期版)

【英語タイトル】Neuroblastoma - Pipeline Review, H2 2016

Global Markets Directが出版した調査資料(DATA70209277)・商品コード:DATA70209277
・発行会社(調査会社):Global Markets Direct
・発行日:2016年11月30日
・ページ数:366
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥216,000見積依頼/購入/質問フォーム
Site LicenseUSD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
Enterprisewide (Global Site License)USD6,000 ⇒換算¥648,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、世界における神経芽細胞腫(Neuroblastoma)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。
・イントロダクション
・神経芽細胞腫(Neuroblastoma)の概要
・神経芽細胞腫(Neuroblastoma)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・神経芽細胞腫(Neuroblastoma)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・神経芽細胞腫(Neuroblastoma)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・神経芽細胞腫(Neuroblastoma)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Neuroblastoma – Pipeline Review, H2 2016

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Neuroblastoma – Pipeline Review, H2 2016, provides an overview of the Neuroblastoma (Oncology) pipeline landscape.

Neuroblastoma is the cancer of the nerve tissues and neural crest cells of adrenal glands, neck, chest or spinal cord, occurring predominantly in children. It usually begins in the adrenal glands further spreading to other parts of the body. The predisposing factors involved in neuroblastoma include genetic conditions. Symptoms include lump in abdomen or chest, weakness, bone pain, breathing problems, dark circles around the eyes and difficulty in movement. The condition may be diagnosed by X-ray imaging, CT scan, MRI, biopsy, urine test, etc. It may be controlled by chemotherapy, radiation therapy, stem cell transplants and medication such as monoclonal antibody regimens.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Neuroblastoma – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Neuroblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuroblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Neuroblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 15, 15, 1, 43 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 8, 7, 9 and 4 molecules, respectively.Neuroblastoma.

Neuroblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Neuroblastoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Neuroblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Neuroblastoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Neuroblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Neuroblastoma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Neuroblastoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Neuroblastoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Table of Contents 2
Introduction 5
Neuroblastoma Overview 6
Therapeutics Development 7
Neuroblastoma – Therapeutics under Development by Companies 9
Neuroblastoma – Therapeutics under Investigation by Universities/Institutes 13
Neuroblastoma – Pipeline Products Glance 15
Neuroblastoma – Products under Development by Companies 18
Neuroblastoma – Products under Investigation by Universities/Institutes 23
Neuroblastoma – Companies Involved in Therapeutics Development 25
Neuroblastoma – Therapeutics Assessment 77
Drug Profiles 95
Neuroblastoma – Dormant Projects 338
Neuroblastoma – Discontinued Products 342
Neuroblastoma – Product Development Milestones 343
Appendix 353

List of Tables
Number of Products under Development for Neuroblastoma, H2 2016 19
Number of Products under Development for Neuroblastoma - Comparative Analysis, H2 2016 20
Number of Products under Development by Companies, H2 2016 21
Number of Products under Development by Companies, H2 2016 (Contd..1) 22
Number of Products under Development by Companies, H2 2016 (Contd..2) 23
Number of Products under Development by Companies, H2 2016 (Contd..3) 24
Number of Products under Investigation by Universities/Institutes, H2 2016 26
Comparative Analysis by Late Stage Development, H2 2016 27
Comparative Analysis by Clinical Stage Development, H2 2016 28
Comparative Analysis by Early Stage Development, H2 2016 29
Products under Development by Companies, H2 2016 30
Products under Development by Companies, H2 2016 (Contd..1) 31
Products under Development by Companies, H2 2016 (Contd..2) 32
Products under Development by Companies, H2 2016 (Contd..3) 33
Products under Development by Companies, H2 2016 (Contd..4) 34
Products under Investigation by Universities/Institutes, H2 2016 35
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 36
Neuroblastoma - Pipeline by Ability Pharmaceuticals SL, H2 2016 37
Neuroblastoma - Pipeline by Acetylon Pharmaceuticals Inc, H2 2016 38
Neuroblastoma - Pipeline by Advanced Accelerator Applications SA, H2 2016 39
Neuroblastoma - Pipeline by Alissa Pharma, H2 2016 40
Neuroblastoma - Pipeline by Ampio Pharmaceuticals Inc, H2 2016 41
Neuroblastoma - Pipeline by APEIRON Biologics AG, H2 2016 42
Neuroblastoma - Pipeline by AstraZeneca Plc, H2 2016 43
Neuroblastoma - Pipeline by Bayer AG, H2 2016 44
Neuroblastoma - Pipeline by Bellicum Pharmaceuticals Inc, H2 2016 45
Neuroblastoma - Pipeline by Bexion Pharmaceuticals LLC, H2 2016 46
Neuroblastoma - Pipeline by BioLineRx Ltd, H2 2016 47
Neuroblastoma - Pipeline by Bionucleon Srl, H2 2016 48
Neuroblastoma - Pipeline by Biotec Pharmacon ASA, H2 2016 49
Neuroblastoma - Pipeline by Cancer Prevention Pharmaceuticals, Inc., H2 2016 50
Neuroblastoma - Pipeline by Cebiotex SL, H2 2016 51
Neuroblastoma - Pipeline by Celgene Corp, H2 2016 52
Neuroblastoma - Pipeline by Cielo Therapeutics Inc, H2 2016 53
Neuroblastoma - Pipeline by Cleveland BioLabs Inc, H2 2016 54
Neuroblastoma - Pipeline by Codagenix, Inc., H2 2016 55
Neuroblastoma - Pipeline by CorMedix Inc, H2 2016 56
Neuroblastoma - Pipeline by Curis Inc, H2 2016 57
Neuroblastoma - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2016 58
Neuroblastoma - Pipeline by DEKK-TEC Inc, H2 2016 59
Neuroblastoma - Pipeline by EnGeneIC Ltd, H2 2016 60
Neuroblastoma - Pipeline by Errant Gene Therapeutics LLC, H2 2016 61
Neuroblastoma - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 62
Neuroblastoma - Pipeline by GlaxoSmithKline Plc, H2 2016 63
Neuroblastoma - Pipeline by Green Cross Cell Corp, H2 2016 64
Neuroblastoma - Pipeline by Ignyta Inc, H2 2016 65
Neuroblastoma - Pipeline by Incuron, LLC, H2 2016 66
Neuroblastoma - Pipeline by Juno Therapeutics Inc, H2 2016 67
Neuroblastoma - Pipeline by Kolltan Pharmaceuticals Inc, H2 2016 68
Neuroblastoma - Pipeline by Lindis Biotech GmbH, H2 2016 69
Neuroblastoma - Pipeline by MabVax Therapeutics Holdings Inc, H2 2016 70
Neuroblastoma - Pipeline by MediaPharma srl, H2 2016 71
Neuroblastoma - Pipeline by Merck & Co Inc, H2 2016 72
Neuroblastoma - Pipeline by Merrimack Pharmaceuticals Inc, H2 2016 73
Neuroblastoma - Pipeline by Morphogenesis Inc, H2 2016 74
Neuroblastoma - Pipeline by Novartis AG, H2 2016 75
Neuroblastoma - Pipeline by Novogen Ltd, H2 2016 76
Neuroblastoma - Pipeline by OGD2 Pharma SAS, H2 2016 77
Neuroblastoma - Pipeline by Pfizer Inc, H2 2016 78
Neuroblastoma - Pipeline by Pharmacyclics Inc, H2 2016 79
Neuroblastoma - Pipeline by Progenics Pharmaceuticals Inc, H2 2016 80
Neuroblastoma - Pipeline by ProNAi Therapeutics Inc, H2 2016 81
Neuroblastoma - Pipeline by Recombio SL, H2 2016 82
Neuroblastoma - Pipeline by Ribomic Inc., H2 2016 83
Neuroblastoma - Pipeline by Sapience Therapeutics Inc, H2 2016 84
Neuroblastoma - Pipeline by Sareum Holdings Plc, H2 2016 85
Neuroblastoma - Pipeline by Shionogi & Co Ltd, H2 2016 86
Neuroblastoma - Pipeline by Syros Pharmaceuticals Inc, H2 2016 87
Neuroblastoma - Pipeline by Tiltan Pharma Ltd, H2 2016 88
Assessment by Monotherapy Products, H2 2016 89
Assessment by Combination Products, H2 2016 90
Number of Products by Stage and Target, H2 2016 92
Number of Products by Stage and Mechanism of Action, H2 2016 98
Number of Products by Stage and Route of Administration, H2 2016 104
Number of Products by Stage and Molecule Type, H2 2016 106
Neuroblastoma - Dormant Projects, H2 2016 350
Neuroblastoma - Dormant Projects (Contd..1), H2 2016 351
Neuroblastoma - Dormant Projects (Contd..2), H2 2016 352
Neuroblastoma - Dormant Projects (Contd..3), H2 2016 353
Neuroblastoma - Discontinued Products, H2 2016 354

List of Figures
Number of Products under Development for Neuroblastoma, H2 2016 19
Number of Products under Development for Neuroblastoma - Comparative Analysis, H2 2016 20
Number of Products under Development by Companies, H2 2016 21
Number of Products under Investigation by Universities/Institutes, H2 2016 25
Comparative Analysis by Late Stage Development, H2 2016 27
Comparative Analysis by Clinical Stage Development, H2 2016 28
Comparative Analysis by Early Stage Products, H2 2016 29
Assessment by Monotherapy Products, H2 2016 89
Number of Products by Top 10 Targets, H2 2016 91
Number of Products by Stage and Top 10 Targets, H2 2016 91
Number of Products by Top 10 Mechanism of Actions, H2 2016 97
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 97
Number of Products by Top 10 Routes of Administration, H2 2016 103
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 103
Number of Products by Top 10 Molecule Types, H2 2016 105
Number of Products by Stage and Top 10 Molecule Types, H2 2016 105

【レポートのキーワード】

神経芽細胞腫(Neuroblastoma)

★調査レポート[神経芽細胞腫(Neuroblastoma):治療薬開発パイプライン動向(2016年下半期版)] (コード:DATA70209277)販売に関する免責事項を必ずご確認ください。
★調査レポート[神経芽細胞腫(Neuroblastoma):治療薬開発パイプライン動向(2016年下半期版)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆